| | 871700-17-3 Basic information More.. |
| Product Name: | Trametinib | | Synonyms: | N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide GSK-1120212;Trametinib (GSK1120212,JTP 74057);Trametinib, >=98%;Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-;N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-tri;N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide;TraMetinib;GSK-1120212(traMetinib,JTP-74057) | | CAS: | 871700-17-3 | | MF: | C26H23FIN5O4 | | MW: | 615.39 | | EINECS: | | | Mol File: | 871700-17-3.mol |  |
Use
Trametinib is an oral MEK inhibitor which has demonstrated excellent results in combination therapy for BRAF-mutated melanoma and is FDA approved in combination with BRAF inhibitors for that indication. Trametinib was evaluated initially as a single agent in KRAS mutant NSCLC in comparison with docetaxel and pemetrexed. Results as a single agent were not impressive, with an ORR of only 12% in these patients.
- Trametinib
-
- US $10.00 / Kg/Drum
- 2023-03-06
- CAS:871700-17-3
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 10 ton
- Trametinib
-
- US $0.00 / KG
- 2023-01-31
- CAS:871700-17-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Trametinib
-
- US $15.00-10.00 / KG
- 2021-07-13
- CAS:871700-17-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
|
871700-17-3
Recommend Suppliers |
|